CO4940427A1 - Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina - Google Patents

Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Info

Publication number
CO4940427A1
CO4940427A1 CO98014184A CO98014184A CO4940427A1 CO 4940427 A1 CO4940427 A1 CO 4940427A1 CO 98014184 A CO98014184 A CO 98014184A CO 98014184 A CO98014184 A CO 98014184A CO 4940427 A1 CO4940427 A1 CO 4940427A1
Authority
CO
Colombia
Prior art keywords
composition
prostaglandine
increasing
present
agent
Prior art date
Application number
CO98014184A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Warren Reed
Yen Shau-Fong
Mary Sou
Flinn Peacock Regina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4940427A1 publication Critical patent/CO4940427A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO98014184A 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina CO4940427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
CO4940427A1 true CO4940427A1 (es) 2000-07-24

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98014184A CO4940427A1 (es) 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Country Status (32)

Country Link
EP (1) EP0969846B2 (enExample)
JP (2) JP4920124B2 (enExample)
KR (1) KR100555818B1 (enExample)
CN (1) CN1236775C (enExample)
AR (2) AR002194A1 (enExample)
AT (1) ATE257385T1 (enExample)
AU (1) AU738781B2 (enExample)
BR (2) BR9808016A (enExample)
CA (1) CA2280089C (enExample)
CL (1) CL2009001870A1 (enExample)
CO (1) CO4940427A1 (enExample)
CY (1) CY2526B1 (enExample)
CZ (1) CZ299833B6 (enExample)
DE (1) DE69820997T3 (enExample)
DK (1) DK0969846T4 (enExample)
EE (1) EE04091B1 (enExample)
ES (1) ES2214706T5 (enExample)
HU (1) HU228896B1 (enExample)
ID (1) ID22389A (enExample)
IL (1) IL131041A0 (enExample)
MY (1) MY122237A (enExample)
NO (1) NO327713B1 (enExample)
NZ (1) NZ337322A (enExample)
PE (1) PE61899A1 (enExample)
PL (1) PL197509B1 (enExample)
PT (1) PT969846E (enExample)
RU (1) RU2197970C2 (enExample)
SI (1) SI0969846T2 (enExample)
TW (1) TW527187B (enExample)
UA (1) UA63938C2 (enExample)
WO (1) WO1998041208A1 (enExample)
ZA (1) ZA982188B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
CA2558135C (en) * 2004-03-18 2012-08-14 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
BRPI0708891A2 (pt) * 2006-03-13 2011-06-28 R Tech Ueno Ltd composição aquosa
US8466174B2 (en) * 2006-03-17 2013-06-18 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
JP2010508306A (ja) * 2006-10-31 2010-03-18 アルコン リサーチ， リミテッド 眼障害を治療するためのｐａｉ−１結合調節因子
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
CN101959500A (zh) * 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
SG11201403013VA (en) 2011-12-07 2014-07-30 Allergan Inc Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
UA121399C2 (uk) 2014-11-25 2020-05-25 Аллерган, Інк. Стабілізовані композиції для офтальмологічного застосування, які містять омега-3-кислоти
WO2020061550A1 (en) * 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059058T3 (es) * 1990-05-22 1994-11-01 R Tech Ueno Ltd Combinacion sinergica para uso oftalmico.
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CA2280089A1 (en) 1998-09-24
ATE257385T1 (de) 2004-01-15
CZ325799A3 (cs) 2000-01-12
KR100555818B1 (ko) 2006-03-03
JP4920124B2 (ja) 2012-04-18
AU7035398A (en) 1998-10-12
NO994481L (no) 1999-09-16
EP0969846B1 (en) 2004-01-07
DK0969846T3 (da) 2004-04-13
NO327713B1 (no) 2009-09-14
AU738781B2 (en) 2001-09-27
EE9900410A (et) 2000-04-17
TW527187B (en) 2003-04-11
DK0969846T4 (da) 2010-12-20
JP2001515502A (ja) 2001-09-18
IL131041A0 (en) 2001-01-28
DE69820997T2 (de) 2004-12-09
CA2280089C (en) 2009-03-03
CN1249687A (zh) 2000-04-05
BR9808016A (pt) 2000-03-08
CN1236775C (zh) 2006-01-18
DE69820997T3 (de) 2011-10-06
CL2009001870A1 (es) 2010-01-22
NO994481D0 (no) 1999-09-16
CY2526B1 (en) 2006-02-08
RU2197970C2 (ru) 2003-02-10
ES2214706T3 (es) 2004-09-16
HK1026841A1 (en) 2000-12-29
NZ337322A (en) 2001-05-25
ZA982188B (en) 1998-09-17
PL335168A1 (en) 2000-04-10
SI0969846T1 (en) 2004-06-30
AR002194A1 (es) 1998-01-07
SI0969846T2 (sl) 2010-12-31
EP0969846B2 (en) 2010-08-25
MY122237A (en) 2006-04-29
PT969846E (pt) 2004-05-31
DE69820997D1 (de) 2004-02-12
HUP0002194A2 (hu) 2000-12-28
HUP0002194A3 (en) 2012-08-28
BRPI9816218B1 (pt) 2016-04-12
CZ299833B6 (cs) 2008-12-10
WO1998041208A1 (en) 1998-09-24
KR20000076330A (ko) 2000-12-26
UA63938C2 (uk) 2004-02-16
EE04091B1 (et) 2003-08-15
PL197509B1 (pl) 2008-04-30
PE61899A1 (es) 1999-06-30
ES2214706T5 (es) 2011-02-02
EP0969846A1 (en) 2000-01-12
JP2010043110A (ja) 2010-02-25
HU228896B1 (en) 2013-06-28
AR011192A1 (es) 2000-08-02
ID22389A (id) 1999-10-07

Similar Documents

Publication Publication Date Title
CO4940427A1 (es) Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina
ES2160631T3 (es) Composiciones de retinoides para aplicacion topica.
RU2291860C3 (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
RU99121641A (ru) Композиции и способы, предназначенные для снижения глазной гипертензии
YU23599A (sh) Stabilizovani antihistaminski sirup
CO4750715A1 (es) Metodos para la limpieza e higiene de productos agricolas, composiciones y articulos de comercio
CO5050388A1 (es) Formulaciones de bromo oxidantes, estables, metodos de fabricacion de las mismas y metodos de uso para el control del microensuciamiento
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
ATE174619T1 (de) Wäschenachbehandlungsmittel
ES2170735A1 (es) Metodo para la preparacion de citalopram.
ES2152517T3 (es) Composicion desodorante.
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
DK1339412T3 (da) Formulering, som indeholder phosphatderivater af elektronoverførselsmidler
DE50106211D1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
ATE270869T1 (de) ZUSAMMENSETZUNG MIT KONTINUIERLICHER WÄSSERIGER PHASE, DIE L-2-OXOTHIAZOLIDIN- 4-CARBONSÄURE ENTHÄLTß.
PT86050A (fr) Procede de regeneration du tournesol par embryogenese
ES2195393T3 (es) Diesteres lipofilos de agentes quelantes.
BR9908217A (pt) Composição desodorante, e, processo para inibição de odor corporal
ES2144768T3 (es) Derivados de bases esfingoides basados en retinoil-amida.
ES2137158T3 (es) N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
JPS53144520A (en) Stabilization of unsaturated tert-amines or their quaternary ammonium salts
GB1472084A (en) Composition and method for sterilizing contact lenses
NO20006197L (no) Anvendelse av minst én syre av sitronsyrecyklusen i kombinasjon med glycerol som et insektsbekjempende middel
PE19798A1 (es) Compuestos fungicidas (b)
MX172053B (es) Proceso para reducir los contaminantes que contienen azufre en hidrocarburos sulfonados, los productos derivados de ellos y los lubricantes que los contienen